Publication date: 08/05/2019
eTheRNA immunotherapies, a clinical-stage company developing cancer immunotherapies from its proprietary mRNA TriMix platform, is expanding its operation into new research laboratories this spring at the Bioscape campus in Ghent, Belgium. This new research base comes in addition to the existing manufacturing and clinical development base in Niel. The new laboratories will accommodate the company’s enlarged research and preclinical teams.
Steven Powell, CEO of eTheRNA immunotherapies, commented: “We are delighted to be opening new research laboratories in Ghent while retaining close links with our founding centre at the VUB university in Brussels. We are looking forward to benefiting from having a presence in one of the leading biotechnology clusters in Europe. Our access to facilities and talent will enable us to accelerate and expand our clinical development programme.
the Bioscape campus in Ghent, where eTheRNA immunotherapies will have its new research base (a high-resolution version of the picture is available upon request: firstname.lastname@example.org)
About eTheRNA immunotherapies
eTheRNA immunotherapies is a clinical-stage company delivering innovative cancer immunotherapies from its proprietary mRNA-based TriMix platform. eTheRNA’s goal is to commercialise these immunotherapies to deliver long lasting clinical remission to cancer patients. eTheRNA was established in January 2013 as a spin-off from the VUB university in Belgium and is backed by international life science investors.
The TriMix platform, on which eTheRNA’s immunotherapies are based, comprises three mRNAs encoding proteins (caTLR4, CD40L and CD70) that work to deliver optimal activation of dendritic cells. These cells behave as immune response mediators and mobilize the immune system to attack cancer cells through inducing a T-cell response. Clinical proof of concept for TriMix-based immunotherapies has been established through an extensive dataset demonstrating clear clinical benefits in advanced melanoma patients.